Skip to content

The Effect of Vırtual Realıty Glasses on Heart Faılure Patıents

Effects of Breathıng Exercıses wıth Vırtual Realıty Glasses on Anxıety Levels, Sleep Qualıty and Respıratory Parameters in Heart Faılure Patıents

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06838169
Enrollment
45
Registered
2025-02-20
Start date
2025-10-01
Completion date
2025-12-30
Last updated
2025-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

Heart failure, Virtual reality glasses, Anxiety, Respiration, Sleep Quality

Brief summary

Anxiety and sleep disorders are among the most common symptoms in heart failure patients. In addition to pharmacological methods for anxiety and sleep disorders, non-pharmacological methods can also be used. Among these, anxiety and sleep disorders can be prevented with virtual reality glasses aimed at distraction. This study will be conducted to evaluate the effect of breathing exercises performed with virtual reality glasses on anxiety, sleep quality, and respiratory parameters. The study will be conducted with a total of 45 patients, 15 virtual reality glasses + breathing exercises, 15 breathing exercises, and 15 controls. Those in the virtual reality glasses + breathing exercises group will perform breathing exercises with virtual reality glasses once a day for 7 days. Those in the breathing exercises group will perform only breathing exercises once a day for 7 days. Anxiety, sleep disorders, and respiratory parameters of the patients will be examined.

Interventions

BEHAVIORALVirtual reality glasses

virtual reality glasses application

BEHAVIORALbreathing exercise

breathing exercise app

Sponsors

Bayburt University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years of age or older, * Verbal communication, * Place and time oriented, * Without any psychiatric illness, * Patients diagnosed with HF with NYHA class III-IV symptoms, * Left ventricular ejection fraction ≥50% (LVEF-CF/HFpEF), between 40-49% (SEF-CF/HFmrEF), HF below 40% (DEF-CF/HFrEF), * High levels of natriuretic peptides (BNP>35 pg/mL and/or NTproBNP>125 pg/mL), * There is no deformity or diagnosis related to the musculoskeletal system that may prevent breathing exercise, * Chronic diseases such as hypertension (Stage 1 and 2 HT) and diabetes mellitus are stable and the treatment for these diagnoses has not been changed in the last month, * Who have not previously received respiratory exercise training and have not participated in a rehabilitation program, * Patients who volunteer to participate in the study will be included in the study

Exclusion criteria

* Life signs are so abnormal as to preclude intervention, * Patients with migraine, vertigo, active nausea-vomiting, headache, dizziness will not be included in the study.

Design outcomes

Primary

MeasureTime frameDescription
Anxiety levelApply the morning before application and the morning 7 days after application.Turkish adaptation of the state-trait anxiety inventory short version (STAIS-5, STAIT-5). This form is a 4-point Likert type. It is an easy-to-apply inventory consisting of a total of 10 statements. As the score obtained in this form increases, the level of anxiety also increases.

Secondary

MeasureTime frameDescription
Sleep QualityApply the morning before application and the morning 7 days after application.Richard Campbell Sleep Quality Scale (RCSQ) for sleep quality level assessment.This form is a 6-item scale. According to the scale scoring, a score between 0-25 indicates very poor sleep, and a score between 76-100 indicates very good sleep.

Countries

Turkey (Türkiye)

Contacts

Primary ContactServet KALYONCUO
servetkalyoncu38@gmail.com(458) 211-1176
Backup ContactÖzlem CEYHAN
ozlemg@erciyes.edu.tr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026